News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Novartis International AG Painkiller Prexige Gets “Not Approvable” Letter in U.S.
September 27, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Sept 27 (Reuters) - U.S. regulators have rejected Novartis AG's (NOVN.VX: Quote, Profile, Research) Prexige painkiller, a move that had been expected after Australia withdrew the drug on concerns over liver side-effects.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Patents
Moderna Notches Much-Needed Win in COVID-19 Patent Spat With Roivant
March 4, 2026
·
2 min read
·
Tristan Manalac
Rare disease
UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism
March 2, 2026
·
3 min read
·
Heather McKenzie
Approvals
Ascendis Enters Achondroplasia Arena as FDA Approves First Weekly Drug
March 2, 2026
·
2 min read
·
Tristan Manalac
CDC
RFK Jr. Appoints 2 New Advisors to CDC Vaccine Panel Ahead of March Meeting
March 2, 2026
·
2 min read
·
Tristan Manalac